Using general Japanese populations, we performed a replication study of genetic loci previously identified in European-descent populations as being associated with uric acid and gout. The relative contribution of non-genetic and genetic factors to the variances in serum uric acid concentration was then evaluated. Methods: Seven single nucleotide polymorphisms (SNPs) were genotyped from 7 candidate loci robustly confirmed in Europeans. Genotyping was performed in up to 17,226 individuals, from which 237 hyperuricemia cases and 3,218 controls were chosen for a case-control study. For 6 SNPs showing a replication of uric acid association in 17,076 general population samples, we further tested the associations with other metabolic traits (n ≤ 5,745) and with type 2 diabetes (931 cases and 1404 controls) and coronary artery disease (806 cases and 1337 controls). Results: Significant uric acid associations (one-tailed p＜0.05) were replicated for 6 loci in Japanese. The strongest association was detected at SLC22A12 rs505802 for uric acid (p = 2.4×10
uricemia is related not only to an increased risk of gout, one of the most common forms of arthritis, but also to an increased risk of cardiovascular disease 1) . Since the mid-1950s and early 1960s, a number of epidemiological studies have reported positive associations between serum uric acid concentration and a variety of cardiovascular conditions, including coronary artery disease (CAD) and kidney disease 2, 3) . Although the relative importance of these associations remains controversial, there seems to be some evidence
Methods

Study Populations
We performed a replication study of previously identified variants in the general Japanese population (Table 1) . Specifically, 5,695 Japanese participants (referred to hereafter as the Amagasaki Study panel) were consecutively enrolled in the population-based setting as described previously 20) , where serum uric acid concentration was measured for 4,542 individuals, among which 35 individuals were receiving current treatment for gout; and 12,569 other Japanese participants (referred to hereafter as the Fukuoka Cohort Study panel) were randomly selected from residents aged 50-74 years in the general population 21) . While some of the Amagasaki Study panel (414 individuals) had been included in the previous GWA meta-analysis of uric acid in east Asians 19) , we used all the Amagasaki Study samples in the present study to perform systematic and comprehensive evaluation of non-genetic and genetic factors, which is different from the purpose of the GWA scan.
The candidate loci tested in the Amagasaki Study and Fukuoka Cohort Study panels were subjected to tests of hyperuricemia associations in a Japanese casecontrol study panel ( Table 1) . Cases of hyperuricemia (defined as serum uric acid ≥ 7.0 mg/dL) comprised 237 individuals who were enrolled from the annual medical checkup in the Amagasaki cohort (n = 87) and the outpatient clinic at the National Center for Global Health and Medicine Hospital (n = 150). Here, 78% of cases (185 of 237 individuals) were under current medication for hyperuricemia or gout. Also, 3,218 controls were enrolled from the Amagasaki Study panel according to the following criteria: [1] no past history and no current treatment of hyperuricemia and gout; and [2] serum uric acid, ＜6.0 mg/dL. In total, 17,226 Japanese individuals were used for testing associations with uric acid and hyperuricemia. Although the samples in the Amagasaki Study overlapped in the two types of analyses, we performed the case-control study as a secondary analysis, which could allow for assessment of the genetic impact on the clinical entity of hyperuricemia within the population.
As part of the present study, we tested associations between SNPs showing a replication of uric acid association and other metabolic traits -fasting plasma glucose (FPG), lipid concentration, body mass index (BMI), and blood pressure-in the Amagasaki Study panel. We further examined the genetic associations in silico with type 2 diabetes (T2D) and CAD, using GWA-scanned data sets from our previous publications: 931 cases and 1,404 controls for T2D 22) and for the clinical benefit of lowering uric acid concentration in the prevention or treatment of cardiovascular disease 1) . Whether it is an independent risk factor for the development of cardiovascular disease or not, elevated serum uric acid concentration is often associated with other established risk factors, such as obesity, hypertension, diabetes, and dyslipidemia 3, 4) . Lifestyle influences (e.g., excess alcohol intake) are known to elevate serum uric acid concentration 5) . The prevalence of hyperuricemia in Japanese men increased from 5% in the 1960s to 20% in the 1990s 6) , which appears to largely result from lifestyle changes in the Japanese. On the other hand, an appreciable contribution of genetic factors to the inter-individual variation in serum uric acid concentration has been documented by epidemiological studies 7, 8) ; for example, the heritability of serum uric acid concentration was estimated to be 63% in the Framingham Heart Study 8) . Supporting this, recent genome-wide association (GWA) studies have identified genetic determinants of serum uric acid concentration and gout [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . Some of the loci identified by GWA studies are in or near genes previously known to influence serum uric acid concentration, whereas others are not; that is, they are located near genes not previously implicated in uric acid metabolism or in the intergenic regions. As these GWA studies were conducted almost exclusively in populations of European descent [9] [10] [11] [12] [13] [14] [15] , studies in non-European populations [16] [17] [18] [19] will allow us to assess the relevance of the findings to other ethnic groups. The effects of some genetic variants on uric acid concentration and hyperuricemia may be enlarged in specific ethnic groups, presumably due to substantial differences in lifestyle factors.
Aim
To test genetic associations with serum uric acid concentration and the risk of hyperuricemia at 7 candidate loci previously reported in European-descent populations [9] [10] [11] [12] [13] [14] [15] , we performed a replication study in Japanese involving 17,076 participants in populationbased cohorts and 150 participants in a hospital-based cohort, followed by examining the relevance of associated SNPs to other cardiovascular risk traits. Further, we evaluated the relative contribution of non-genetic and genetic factors to the variances in serum uric acid concentration, and gene-environment interactions among the general Japanese population samples.
not strictly under the condition of an overnight fast, it was not used for tests of association with either FPG or lipid concentration.
All participants enrolled in these different studies provided written informed consent, and the local ethics committees approved the protocols used. 806 cases and 1,337 controls for CAD 23) .
In the Amagasaki Study panel, blood samples that were collected after ≥ 6 hours fast and had measurement data on the corresponding phenotypes were used for tests of association with FPG (n = 4,813) and lipid concentration (n = 4,990). In the Fukuoka Cohort Study panel, on the other hand, as blood was drawn Values are the means±SD unless otherwise indicated. All clinical assessments were performed using uniform standards in each population. Blood samples were taken after ≥ 6 hours fast in the Amagasaki Study panel; without setting strict fasting condition in the Fukuoka Cohort Study panel. Since the questionnaire did not differeniate the category of occasional drinker from that of current drinker, the corresponding subjects are combined in the category of current drinker in the Fukuoka Cohort Study panel. † HbA1c was measured for 596 subjects in the Amagasaki Study panel, whereas for all participants in the Fukuoka Cohort Study panel. ‡ LDL cholesterol was calculated in the Amagasaki Study panel using the Friedewald formula, with missing values assigned to individuals with triglycerides ＞400 mg/dL. Since blood samples were taken without setting a strict fasting condition, the values of LDL cholesterol and the prevalence of dyslipidemia are not shown for the Fukuoka Cohort Study panel according to the Japan Atherosclerosis Society Guidelines (ref. 42) . Hypertension is defined when systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg, or taking antihypertensive medication. Diabetes is defined when fasting plasma glucose ≥ 7.0 mmol/L and/or HbA1c ≥ 6.5%, or taking blood glucose lowering medication. Dyslipidemia is defined according to the Japan Atherosclerosis Society Guidelines (ref. 42) . # Unaffected controls were some of the participants in the Amagasaki Study, who were selected with the following criteria: no treatment of gout/ hyperuricemia and serum uric acid ≤ 6.0 mg/dL. in HapMap JPT＋CHB; rs780093 for rs780094, rs13129697 for rs1014290, rs4148155 for rs2231142, rs1183201 for rs1165196, and rs506338 for rs505802)
were tested for SNP-uric acid association at the corresponding loci. For the purpose of comprehensive evaluation (e.g., test of gene-environment interaction and cumulative genetic effect) in the general populations, all the Amagasaki Study samples consecutively enrolled are included in the present study. ables on uric acid concentration, multiple regression analysis was performed using the Amagasaki Study panel. The tested predictor variables included gender, BMI, age, creatinine, γGTP, triglyceride, systolic and diastolic blood pressure, alcohol intake, and SNPs showing a replication of uric acid association. Alcohol intake was self-reported as the usual amounts that were denoted in terms of servings of sake (1 gou (180 mL) of Japanese rice wine is considered equal to 22 g ethanol).
To collectively assess the proportion of variance for uric acid concentration, explained by individual variables, the coefficient of determination (R 2 ) was calculated.
Genetic Risk Score
A genetic risk score was generated for every individual by counting the number of alleles associated with higher uric acid concentration (the "risk" alleles of 6 associated SNPs, range 0-12). Among 2,382 men aged 30-69 years in the Amagasaki Study panel, the relative risk (RR) of hyperuricemia was calculated by comparing a case group (individuals with a given genetic risk score) and a common control group (i.e., an entire sample of 2,382 men). This could estimate whether belonging to a particular case group increases or decreases an individual's risk of developing hyperuricemia as compared to that of a population mean.
Results
Association with Uric Acid and Hyperuricemia at Reported Loci
In this study, uric acid and hyperuricemia association was tested with 7 SNP loci that had attained genome-wide significance levels (p＜5×10 −8 ) in previously performed GWA studies for uric acid (and gout) in Europeans [9] [10] [11] [12] [13] [14] [15] . In the combined Japanese sample (n = 17,076; Table 3 ) as well as individual study panels ( Table 2) , we found nominally significant (two-tailed p＜0.1) associations of 6 SNPs with uric acid; they were rs780094 (GCKR), rs1014290 (SLC2A9), rs2231142 (ABCG2), rs742132 (LRRC16A), rs1165196 (SLC17A1-A3), and rs505802 (SLC22A12). The strength of the association with uric acid was comparable between the study panels (Amagasaki vs. Fukuoka) ( Table 2) .
Nominally significant associations with hyperuricemia were also found at 3 SNP loci -rs1014290 (SLC2A9), rs2231142 (ABCG2), and rs505802 (SLC22A12) in the Japanese. When we compared the effect sizes for continuous (uric acid) and dichotomous (hyperuricemia) traits associations of the tested SNPs, there was an overall fair correlation despite some deviations at rs2231142 (ABCG2) and rs505802
SNP Genotyping and Quality Control
Samples were genotyped using the TaqMan assay for 7 SNPs from 7 uric acid loci robustly confirmed in populations of European descent [9] [10] [11] [12] [13] [14] [15] . These SNPs included rs12129861 (PDZK1), rs780094 (GCKR), rs1014290 (SLC2A9), rs2231142 (ABCG2), rs742132 (LRRC16A), rs1165196 (SLC17A1-A3), and rs505802 (SLC22A12). Because rs12356193 (SLC16A9) was not polymorphic in the Japanese, it was not tested for replication. The genotype distribution of all tested SNPs was in Hardy-Weinberg equilibrium (p＞10 −4 ). We obtained successful genotyping call rates of ＞99.6% for all SNPs and ＞99.8% for the whole characterized sample (across 7 SNPs).
Statistical Analyses
SNP Association Analysis
The SNPs were tested for association with uric acid concentration and hyperuricemia using linear regression analysis and the Cochran-Armitage trend test, respectively. In the linear regression models, continuous uric acid traits were adjusted for age and BMI separately by gender, and for alcohol drinking (drinker or non-drinker). In the replication study, one-tailed p＜0.05 (i.e., two-tailed p＜0.1) was considered statistically significant for the loci previously shown to have genome-wide significant (p＜5×10 −8 ) association in Europeans [9] [10] [11] [12] [13] [14] [15] ; for an association to be considered significant, it had to involve the same coded allele as that reported in Europeans and was accordingly assessed with the one-tailed test. Otherwise, a significance level was set at p＜0.05 after adjustment for multiple testing with Bonferroni's correction. For the purpose of uniformity, two-tailed p values are shown throughout the text, unless otherwise indicated. Association results were combined for the 2 Japanese panels using the inverse variance method ( Table 2) . PLINK 24) , R software (version 2.10.0; http://cran.r-project.org/), and the rmeta and meta packages were used to test for the associations.
Test of Ethnic Heterogeneity
The per-allele effect size of an SNP on uric acid concentration (in β) and hyperuricemia (in odds ratio (OR)) was compared between the ethnic groups. Uric acid concentration was standardized as a z-score within each ethnic group before cross-population comparison. The interaction of effect estimates with ethnicity (Japanese vs. European) was analyzed by Cochran's Q-test 25) .
Linear Regression Analysis for Uric Acid Concentration
To test the influences of potential risk factor vari- in HapMap JPT＋CHB; rs780093 for rs780094, rs13129697 for rs1014290, rs4148155 for rs2231142, rs1183201 for rs1165196, and rs506338 for rs505802)
were tested for SNP-uric acid association at the corresponding loci. For the purpose of comprehensive evaluation (e.g., test of gene-environment interaction and cumulative genetic effect) in the general populations, all the Amagasaki Study samples consecutively enrolled are included in the present study. †
The detailed results for genotype-BMI and genotype-drinking interactions by multiple linear regression are shown in Supplementary Table 3. (SLC22A12) (Fig. 1) . This appeared to reflect pronounced changes in coded allele frequency (CAF) in the higher (for rs2231142) and lower (for rs505802) parts of trait distribution in the Japanese general population, when arranged according to uric acid concentration (Fig. 2) . Among the 7 tested loci, significant (p＜0.05/7 ≈ 0.007) cross-population heterogeneity was detected for rs1014290 (SLC2A9), rs1165196 (SLC17A1-A3), and rs505802 (SLC22A12) ( Table 4) , where the strongest association with uric acid was observed for different loci: rs505802 (SLC22A12) in Japanese (β= 0.246 mg/dL) and rs1014290 (SLC2A9) in Europeans (β= 0.341 mg/dL). The variance for uric acid that was explained by the associated SNPs totaled 3% in the Japanese.
Factors Modulating Genetic Associations
To assess the impact of cardiovascular risk traits 
Figure S1
Relationship between uric acid β coefficients (x-axis) and hyperuricemia ORs (y-axis) across 95% CIs for individual estimates of OR and β coefficient were plotted as vertical and horizont respectively. 
rs2231142, male
Quantiles by uric acid level Coded allele frequency ; Table 6A ). There was no significant interaction between genotype and BMI ( Table 3 and  Table 6B ), whereas there was a nominally significant interaction between genotype and drinking for rs1165196 (SLC17A1-A3) (p = 0.003; Table 3 and  Table 6C ).
Cumulative Effect of 6 Associated Loci on Hyperuricemia
Across the genetic risk score groups, the RR of hyperuricemia increased in a stepwise fashion in the Japanese ( Fig. 3 ; p = 2.0×10 −11 for trend of genetic risk score). We found a 2.5-fold variation in hyperuricemia prevalence from the lowest (score ≤ 5, RR = on uric acid variance in the Japanese, we first performed linear regression analysis with the Amagasaki Study panel ( Table 5 ). Sex was found to be a principal predictor (R 2 = 0.254); BMI (R 2 = 0.042), creatinine (R 2 = 0.044), γGTP (R 2 = 0.031), and triglyceride (R 2 = 0.020) levels were ranked in second to fifth places. In addition to these variables, although modest in the explained variance (R 2 ), alcohol intake and systolic and diastolic blood pressure correlated with uric acid elevation (R 2 = 0.008 to 0.011), which was found to be almost equivalent to the variance explained by top two SNP loci in the studied population -rs505802 (SLC22A12; R 2 = 0.01) and rs1014290 (SLC2A9; R 2 = 0.008) in the multivariate model. Then, we analyzed uric acid associations separately by sex; significant (p＜0.05/7 ≈ 0.007) sexual variant loci influencing uric acid concentration are reproducible in 17,076 Japanese general population samples (Table 3) , with the presence of some degree of ethnic diversity in uric acid variants (Table 4) . While genetic associations with uric acid have been replicated or identified in Japanese GWA study 18) , east Asian GWA meta-analysis 19) , and several other studies focused on particular target gene variants [27] [28] [29] [30] [31] [32] , to our knowledge, this is the first study that has systematically evaluated the relative contribution of non-genetic and genetic factors to the variances for serum uric acid concentration and their potential interactions in the Japanese. Despite the small number of SNP loci described here (6 SNPs) and the small proportion of uric acid variation explained by these SNPs (R 2 = 0.03), our data show that the joint effect of multiple risk alleles on uric acid concentration and hyperuricemia is more or less comparable to that of 2 wellrecognized risk factors -BMI and alcohol intake ( Table 5 and Fig. 3 and 4) . Our data also indicate in the Japanese a lack of evidence for a significant causal relationship between serum uric acid and cardiovascular risk factors and CAD (Fig. 5) , which stands in contrast to the associations observed in epidemiological studies.
0.62) to the highest (score ≥ 10, RR = 1.54) risk score groups for the combination of 6 associated loci in our study. Separately by sex, the contribution of the genetic risk score to the variance of uric acid was compared to the variance of the trait explained by BMI and alcohol intake (Fig. 4) .
Genetic Association with Other Risk Factor Traits
We tested the association of the 6 uric acid loci with cardiovascular risk traits to examine a potential causal relation between them (Fig. 5 and Table 7 ). Of the 6 SNPs, rs780094 (GCKR) showed significant (p＜0.05/6 ≈ 0.008) association with FPG (β=−0.032 mmol/L, p = 0.002) 26) and triglyceride levels (β=0.026 mg/dL, p=6.2×10 −10 ) as we reported elsewhere (manuscript submitted). Although not reached the threshold, rs780094 (GCKR) also showed borderline association with T2D (OR = 0.87, p = 0.016; the A-allele assigned as a coded allele across the trait associations). No other significant association was detected between the 6 SNP loci and cardiovascular risk traits.
Discussion
The present study confirmed that 6 common For each predictor variable, the linear regression for uric acid concentration was adjusted for BMI and age, separately by sex; however, p value and R 2 were calculated using ANOVA for sex, BMI, and age. Variables showing a highly significant (p＜1× 10 −13 except for age) association with uric acid concentration are listed in the table. The estimate and SE were first calculated for the natural logarithm of γ-GTP level, and then retransformed by being divided by 16 (IU/L), which is the median γ-GTP level. † The estimate and SE were first calculated for the natural logarithm of triglyceride level, and then retransformed by being divided by 90 (mg/dL), which is the median trigliceride level. ‡ One gou [180 mL] unit of Japanese rice wine amounts to 22 g ethanol. tion 33) ; and that the subjects totaled 17,076 (females= 52.1%), belonging to a wide range of age groups (18 to 97 years). In the general population, marked sex differences are widely recognizable in uric acid con-
The strength of the present study is that we used 2 independent cohorts of the Japanese general population; that the study subjects were enrolled from regions of Japan with no strong population stratifica- Effects of genotype (SNP), BMI, and their interaction on uric acid concentration were analyzed by linear regression after adjustment for sex-specific age. The analysis was performed on 17,076 participants in both the Amagasaki and Fukuoka Cohort Studies, except for PDZK1, which was tested for association only in the Amagasaki Study. Effects of genotype (SNP), drinking (alcohol units/week), and their interaction on uric acid concentration were analyzed by linear regression after adjustment for sex-specific BMI and age. The analysis was performed on 1,417 drinkers (for whom the detailed information about alcohol units/week was available) and 2,337 non-drinkers in the Amagasaki Study.
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Genetics of Uric Acid and Hyperuricemia phism have been reported for the SLC2A9 locus in Europeans 11) , showing that the causative variant(s) could exert sex-specific effects that are inverted compared to what is generally recognized for uric acid in epidemiological studies.
Further, according to our assessment in the Amagasaki Study panel, 2 well-recognized modifiable risk factors for hyperuricemia -BMI and alcohol intake-show a significant association with serum uric acid concentration (R 2 = 0.042 for BMI and 0.009 for alcohol intake; Table 5 ). When we arbitrarily categocentration and the prevalence of hyperuricemia, in which sex steroids such as estrogen are assumed to play some role in uric acid regulation 1, 34) . Against this background, we examined the modulation of SNPuric acid association by sex ( Table 6A ) and found that genetic impacts of an SNP rs1014290 (SLC2A9) on uric acid significantly differed between sexes (β= 0.101 mg/dL in men and 0.254 mg/dL in women, R 2 = 0.002 in men and 0.026 in women; p=5.1×10 −9 ); that is, a 2.5-fold larger effect size in women than in men. The corresponding findings of sexual dimor- Fig. 3 . Effects of genetic risk score, BMI, and alcohol intake on the prevalence of hyperuricemia. Among 2,382 men aged years in the Amagasaki Study panel, we calculated the relative risk (RR) of hyperuricemia by comparison between a case group (individuals with a given genetic risk score) and a common control group (i.e., an entire sample of 2,382 men) (see Methods). The participants were arbitrarily categorized into 5-6 subgroups with regard to BMI (middle) and alcohol intake (right) as well as a genetic risk score (left) generated from 6 associated SNPs. It is depicted as a proportion of the total variance of the trait (2.2% in men and 3.6% in women) compared to the variance of the trait explained by BMI (6.5% in men and 7.7% in women), and alcohol intake (1.2% in men and 2.2% in women); the figures were estimated in the Amagasaki Study panel (2490 men and 1978 women with complete observations for the corresponding traits). There is no significant interaction (p＞0.05) between the genetic risk score, and BMI and alcohol intake.
style modification for hyperuricemic individuals should be made independently of genetic information on common variants influencing uric acid. Five (SLC2A9, ABCG2, SLC17A1-A3, SLC22A12, and LRRC16A) of the 7 tested loci showed genomewide significant (p＜5×10 −8 ) associations with uric acid in the Japanese population. The above-listed genes are located near the most strongly associated rized the participants into 5-6 subgroups with regard to BMI and alcohol intake as well as a genetic risk score generated from 6 associated SNPs, the RR of hyperuricemia increased in a stepwise fashion to an almost comparable extent, among the 3 variables (Fig. 3) . As we saw a slight significant interaction of the tested SNPs with BMI and alcohol intake ( Table  3 and Table 6B and 6C), a recommendation of life- Variables adjusted in the regression models are: age classes by sex for BMI (normalized); sex, age, age this approach, such as pleiotropy (or multi-function) of genes, which was indeed the case with the GCKR locus, careful interpretation is required because of our failure to demonstrate an association between genotype and CAD.
Conclusion
We confirmed the replication of 6 genetic loci associated with serum uric acid concentration in the Japanese general population, with some inter-ethnic heterogeneity in the strength of association. The combined genetic effect as summarized in a genetic risk score is associated with a 2.5-fold increase in the RR of hyperuricemia and can also explain some proportion of inter-individual variation in uric acid, more or less comparable to that for BMI and alcohol intake. This should be considered in our decision of an individual's treatment strategy for hyperuricemia, although the impacts of currently-known genetic factors are much weaker than those of modifiable risk factors.
